Abstract
Erectile dysfunction (ED) is a major health problem as the population ages. Basic science research for the last two decades has expanded the knowledge on ED and identified several key molecular changes associated with the pathogenesis of ED, including nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) / protein kinase G (PKG) pathway, RhoA/Rho-associated protein kinase (ROCK) signaling pathway, reactive oxygen species (ROS), renin-angiotensin system (RAS) and tumor necrosis factor-alpha (TNF-α). The causes of ED are classified into aging, vasculogenic, neurogenic, endocrinological, drug-induced and psychogenic. ED is often associated with systemic diseases, such as diabetes and cardiovascular diseases. In this review, we will review the molecular mechanisms of ED and known mechanisms behind ED associated with systemic diseases.
Keywords: Angiotensin, erectile dysfunction, nitric oxide, pathophysiology, reactive oxygen species, RhoA/Rho-associated protein kinase, tumor necrosis factor-alpha.
Current Drug Targets
Title:Pathophysiology of Erectile Dysfunction
Volume: 16 Issue: 5
Author(s): Hotaka Matsui, Nikolai A. Sopko, Johanna L. Hannan and Trinity J. Bivalacqua
Affiliation:
Keywords: Angiotensin, erectile dysfunction, nitric oxide, pathophysiology, reactive oxygen species, RhoA/Rho-associated protein kinase, tumor necrosis factor-alpha.
Abstract: Erectile dysfunction (ED) is a major health problem as the population ages. Basic science research for the last two decades has expanded the knowledge on ED and identified several key molecular changes associated with the pathogenesis of ED, including nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) / protein kinase G (PKG) pathway, RhoA/Rho-associated protein kinase (ROCK) signaling pathway, reactive oxygen species (ROS), renin-angiotensin system (RAS) and tumor necrosis factor-alpha (TNF-α). The causes of ED are classified into aging, vasculogenic, neurogenic, endocrinological, drug-induced and psychogenic. ED is often associated with systemic diseases, such as diabetes and cardiovascular diseases. In this review, we will review the molecular mechanisms of ED and known mechanisms behind ED associated with systemic diseases.
Export Options
About this article
Cite this article as:
Matsui Hotaka, A. Sopko Nikolai, L. Hannan Johanna and J. Bivalacqua Trinity, Pathophysiology of Erectile Dysfunction, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/138945011605150504114041
DOI https://dx.doi.org/10.2174/138945011605150504114041 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia in Du-145 Prostate Cancer Xenografts After Estramustine Phosphate and Radiotherapy
Current Radiopharmaceuticals HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Metallic Nanopopcorns: A New Multimodal Approach for Theranostics
Current Nanoscience STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry The Effects of Dietary Factors on the Androgen Receptor and Related Cellular Factors in Prostate Cancer
Current Medicinal Chemistry Safety of Nanoparticles in Medicine
Current Drug Targets GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Breakthrough Pain
Current Drug Therapy Cytochrome P450 in Neurological Disease
Current Drug Metabolism Meet the Editorial Board
Current Drug Targets Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology A Review of Accelerator-Produced Ga-68 with Solid Targets
Current Radiopharmaceuticals The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions
Current Drug Metabolism GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Suramin: Clinical Uses and Structure-Activity Relationships
Mini-Reviews in Medicinal Chemistry EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets